Moving into the next era of PET myocardial perfusion imaging: introduction of novel 18F-labeled tracers

Abstract

The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 18 F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 18 F-labeled perfusion radiotracers will be discussed. Electronic supplementary material The online version of this article (10.1007/s10554-018-1469-z) contains supplementary material, which is available to authorized users.

11C-PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study

“…Not surprisingly, 99m Tc-MAG3 is the radiotracer of choice in clinical routine and used in approximately 70% of the scans in the United States (27). However, recent years have witnessed an expanded use of PET given its advantages over SPECT (28,29).…”

18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

“…flexibility in study design with potential for delayed imaging protocols due to a longer half-life, b.) lower positron energy with resultant short positron range in tissue and improved contrast and noise, and c.) potential for distribution by commercial vendors through existing shipping networks 15, 16. Notably, such dispatch systems from central cyclotron facilities to smaller hospitals have led to remarkable cost-savings for [ 18 F]FDG 17.…”

Novel Functional Renal PET Imaging With 18F-FDS in Human Subjects

“…Notably, 18 F-FDS can be easily produced from the most commonly used PET radiotracer 18 F-FDG, providing access for virtually any PET facility with radiochemistry infrastructure. Moreover, due to the long half-life (109.4 minutes), delivery from central cyclotron facilities to smaller hospitals can be envisaged, 6 which has been proven to be cost-effective for oncology imaging with 18 F-FDG. 7 18 F-FDS PET has the major advantage of lower positron energy along with higher positron yield, and therefore, the increased count rates offer the opportunity to inject a considerably lower amount of activity.…”